Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform
Novo Nordisk announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi)…
Read More...
Read More...
